Idecabtagene vicleucel for the treatment of patients with relapsed and refractory multiple myeloma after 3 or more treatments

30 November 2023 - NICE is unable to make a recommendation on the use of idecabtagene vicleucel (Abecma) for the treatment ...

Read more →

Tisagenlecleucel for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies

29 November 2023 - NICE is unable to make a recommendation on the use of tisagenlecleucel (Kymriah) for the treatment of ...

Read more →

Tabelecleucel for the treatment of patients with a post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus

19 October 2023 - NICE is unable to make a recommendation on the use of tabelecleucel (Ebvallo) for the treatment of ...

Read more →

Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapy

7 June 2023 - NICE has published final evidence-based recommendations on the use of axicabtagene ciloleucel (Yescarta) for the  treatment ...

Read more →

Brexucabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 26 years and over

7 June 2023 - NICE has published final evidence-based recommendations on the use of brexucabtagene autoleucel (Tecartus) for the treatment ...

Read more →

Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory follicular lymphoma

7 June 2023 - NICE has published evidence-based recommendations on the use of axicabtagene ciloleucel (Yescarta) for the treatment of ...

Read more →

Ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma

17 May 2023 - NICE is unable to make a recommendation on the use of ciltacabtagene autoleucel (Carvykti) for the treatment ...

Read more →

Two new personalised immunotherapy treatments for aggressive forms of blood cancer recommended for the Cancer Drugs Fund

27 April 2023 - NICE recommends two CAR-T therapies, both given as one-off infusions, to treat aggressive forms of blood ...

Read more →

Axicabtagene ciloleucel for the treatment of adults with diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after two or more systemic therapies

28 February 2023 - This appraisal reviews the additional evidence collected as part of the Cancer Drugs Fund managed access ...

Read more →

More than 400 people set to benefit after NICE approves ground-breaking CAR-T therapy to treat aggressive form of blood cancer

26 January 2023 - Hundreds of people with an aggressive form of lymphoma are set to benefit from the first ...

Read more →

Brexucabtagene autoleucel for the treatment of adults with relapsed or refractory B-cell acute lymphoblastic leukaemia

2 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...

Read more →

Axicabtagene ciloleucel for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma after one systemic treatment

23 November 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...

Read more →

Tisagenlecleucel for the treatment of patients with follicular lymphoma after two or more therapies

22 November 2022 - NICE is unable to make a recommendation on the use of tisagenlecleucel for the treatment of adults ...

Read more →

NICE publishes draft guidance on the use of Libmeldy

9 July 2021 - OTL-200 (Libmeldy) is a gene therapy medicinal product that expresses the human ARSA gene. ...

Read more →

NHS patients to benefit from first full access deal in Europe for new CAR-T therapy recommended by NICE

25 February 2021 - NICE has agreed a managed access agreement, via the Cancer Drugs Fund with manufacturer Kite, so more ...

Read more →